Study points to need for Group B Strep vigilance in newborns

03/21/2013 | Minnesota Public Radio

Health experts in Minnesota are expressing concern regarding an increase in cases of a drug-resistant form of Group B Streptococcus called serotype IV. The strain made up 16% of neonatal cases in 2010, according to a study published in the CDC journal Emerging Infectious Diseases. Researcher Dr. Patricia Ferrieri highlighted the importance of watching for signs of drug-resistant Group B Strep in an infant's first days of life.

View Full Article in:

Minnesota Public Radio

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI